A Case of Dexamethasone Intravitreal Implant Fragmentation During the Injection Procedure in Central Retinal Vein Occlusion
Journal of the Korean Ophthalmological Society
; : 982-986, 2013.
Article
in Ko
| WPRIM
| ID: wpr-160286
Responsible library:
WPRO
ABSTRACT
PURPOSE: We report a case of dexamethasone intravitreal implant (Ozurdex(R); Allergan, Inc.) fragmentation during the injection procedure in macular edema due to central retinal vein occlusion. CASE SUMMARY: A 57-year-old man visited our hospital for visual disturbance in his right eye. The patient's best-corrected visual acuity was 0.02 in the right eye and 1.2 in the left eye. After fundus examination, the patient was diagnosed with central retinal vein occlusion with macular edema, thus bevacizumab was injected in the right eye. However, the macular edema did not improve, and a dexamethasone intravitreal implant was injected in the right eye. Immediately after the dexamethasone intravitreal implant injection, on fundus exam, the drug was observed to be fragmented into 3 pieces without any additional treatment. After 2 months, the patient's best-corrected visual acuity was 0.4 in the right eye and 1.2 in the left eye. Macular edema decreased according to optical coherence tomography. CONCLUSIONS: A case of dexamethasone intravitreal implant fragmentation during an injection procedure has not been previously reported in Korea. Although the drug fragmented, the treatment was effective without complications.
Key words
Full text:
1
Database:
WPRIM
Main subject:
Retinal Vein
/
Dexamethasone
/
Visual Acuity
/
Macular Edema
/
Eye
/
Antibodies, Monoclonal, Humanized
/
Bevacizumab
/
Korea
Limits:
Humans
Country/Region as subject:
Asia
Language:
Ko
Journal:
Journal of the Korean Ophthalmological Society
Year:
2013
Document type:
Article